December 5, 2019

Non-Invasive Prenatal Testing Market to Gain a Revenue Worth US$ 5,000 Mn by 2027

Transparency Market Research (TMR) has published a new report titled, “Non-Invasive Prenatal Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.According to the report, the global non-invasive prenatal testing market was valued at US$ 1300 Mn in 2018. It is projected to expand at a CAGR of 16% from 2019 to 2027.

Increasing cases of Downs’ syndrome, rising maternal age, and increasing demand for early and non-invasive fetal testing procedures are anticipated to boost the global non-invasive prenatal testing market from 2019 to 2027.

Stringent regulatory guidelines, limitations of non-invasive prenatal testing, and availabilities of other alternatives would likely to hamper the growth of the global non-invasive prenatal testing market in the future. On the other, emerging non-invasive prenatal testing will prove an opportunity to the global non-invasive prenatal testing market in the upcoming future. North America is expected to dominate the global non-invasive prenatal testing market in the next few years, while the non-invasive prenatal testing market in Asia Pacific is likely to propel at a significant growth rate in the near future.

Request a PDF Sample on Non-Invasive Prenatal Testing Market Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

Materni21 segment to hold prominent market share

Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others. The MaterniT21 segment accounted for a significant share of the global non-invasive prenatal testing market in 2018. The segment is estimated to remain highly lucrative during the forecast period.

In the U.S,, Sequenom (which was presently a part of Labcorp) introduced MateriT21 in 2011, which was the first NIPT solution in the U.S. MaterniT21 is able to identify trisomies and expanded tests may also explain sex chromosomes disabilities and some microdeletions. Less percentage error is a significant advantage of MaterniT21.

In addition to MaternitT21, the Panorama segment held a notable share of the global non-invasive prenatal testing market, in terms of volume, in 2018.

Trisomy segment to expand at rapid pace

In terms of application, the global non-invasive prenatal testing market has been classified into Trisomy, Microdeletions Symptoms, and others (Sex Chromosomes Disorders). The trisomy segment is anticipated to expand at a notable CAGR in the near future. According to the CDC, Down’s syndrome is considered to be a common chromosomal disorder in the U.S.

Around 6,000 babies (1 in 700 babies) are born with Down’s syndrome in the U.S., each year, and a rise in the cases of Down’s syndrome has fueled concerns among healthcare practitioners in the U.S. Increasing new cases of Down’s syndrome among live births in the U.S. is a leading factor attributed to the notable share held by the trisomy segment of the global non-invasive prenatal testing market in 2018.

Diagnostic laboratories segment to expand rapidly

Based on end-user, the global non-invasive prenatal testing market has been divided into hospitals, diagnostic laboratories, and others.

The diagnostic laboratories segment is anticipated to expand at a significant growth rate during the forecast period, due to the emerging healthcare infrastructure in the diagnostic laboratories as compared to hospitals.

Request for a Discount on Non-Invasive Prenatal Testing Market Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=374

North America to account for prominent market share

In terms of revenue, North America dominated the global non-invasive prenatal testing market in 2018.

Higher rate of adoption of non-invasive prenatal testing, rising cases of Down’s syndrome, strong healthcare infrastructure, and presence of key companies are likely to drive the non-invasive prenatal testing market in North America.

NGS (next generation sequencing) segment to hold notable share

Based on technology, the global non-invasive prenatal testing market has been classified into NGS (next generation sequencing), WGS (whole genome sequencing), and others.

The NGS (next generation sequencing) segment accounted for a major share of the global non-invasive prenatal testing market. The segment is anticipated to exhibit a notable attractiveness index in the near future.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving method-ologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of re-search is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Blog: https://theglobalhealthnews.com/